1
|
The Effects of Surgery and Adjuvant Therapy on Survival Outcomes in Clear Cell Ependymomas: A Systematic Review and Meta-Analysis of Individual Patient Data. World Neurosurg 2020; 145:229-240. [PMID: 32949795 DOI: 10.1016/j.wneu.2020.09.044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Revised: 09/10/2020] [Accepted: 09/10/2020] [Indexed: 12/29/2022]
Abstract
BACKGROUND The survival outcomes of clear cell ependymomas are poorly understood. This study clarifies the role of surgery and adjuvant therapy when this morphologically distinct tumor is encountered. METHODS A systematic search for studies relating to clear cell ependymomas was conducted. Primary outcomes were progression-free survival and overall survival. Prognostic variables were age, sex, tumor consistency, extent of resection, and postoperative adjuvant therapy. Kaplan-Meier survival curves were generated and compared by the log-rank test. Multivariate Cox regression models were constructed, interrogated with Schoenfeld residuals, and used to identify independent prognostic factors. RESULTS Of the 384 articles retrieved, 8 articles comprising 77 cases of clear cell ependymoma were included. Five-year overall survival and progression-free survival were 58.1% (95% confidence interval [CI], 46.3%-72.9%) and 46.3% (95% CI, 34.2%-62.8%), respectively. Kaplan-Meier analysis with the log-rank test showed that gross total resection was superior to subtotal resection in prolonging survival (P = 0.047) and delayed time to recurrence (P < 0.01). Multivariate analysis confirmed gross total resection as an independent protective factor against relapse (odds ratio, 0.39; 95% CI, 0.17-0.89; P = 0.03). Age <50 years predicted longer overall survival (odds ratio, 0.16; 95% CI, 0.05-0.49; P < 0.01). Postoperative adjuvant therapy after gross total resection did not affect overall survival (P = 0.98) or progression-free survival (P = 0.93). Adjuvant therapy after subtotal resection favored improved overall survival (P = 0.052). CONCLUSIONS Clear cell ependymomas are particularly aggressive in those aged >50 years. Gross total resection remains the cornerstone of management. Postoperative adjuvant therapy is likely to be of survival benefit only after subtotal resection.
Collapse
|
2
|
Intradural Extramedullary Nonconus Nonfilum Spinal Ependymomas: Report of a Rare Variant and Newer Insights into Their Histogenesis with Proposal of a Classification Scheme and a Management Algorithm Based on a Review of Literature. World Neurosurg 2019; 134:323-336. [PMID: 31682991 DOI: 10.1016/j.wneu.2019.10.152] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Revised: 10/22/2019] [Accepted: 10/23/2019] [Indexed: 11/22/2022]
Abstract
BACKGROUND Ependymomas are common intramedullary spinal tumors but there are scattered reports of this tumor presenting with exophytic growth patterns masquerading as intradural extramedullary (IDEM) tumors. Such IDEM ependymomas are seldom suspected preoperatively and it is only during surgery that their existence is revealed. Little is known of such rare growth patterns of an otherwise common intramedullary spinal cord tumor, their characteristics, and their management considerations. METHODS We present a case of an exophytic dorsal ependymoma with a stalk like attachment to the spinal cord and the surgical management in a 24-year old woman. An extensive literature search was carried out on all prominent databases to find out similar cases reported earlier. We excluded filum/conus ependymoma, purely extradural spinal ependymoma as well as the extraspinal ependymomas. Details of each case reported before were obtained and tabulated. RESULTS IDEM ependymomas have been reported in 54 patients so far, including the present case. Four patterns of growth emerged from the literature review: intramedullary ependymoma with exophytic component (group I, n = 9), exophytic IDEM ependymoma without intramedullary component (group II, n = 6), IDEM ependymoma arising from nerve roots (group III, n = 7), and pure IDEM ependymoma (group IV, n = 32). Except in group I, IDEM ependymoma affects females more frequently, without any specific age predilection. Thoracic spinal cord/canal is the most common location across all groups. Multifocal disease, craniospinal dissemination, and recurrences tend to be maximum in group IV. CONCLUSIONS IDEM ependymomas are more common in thoracic segment of the cord and broadly divisible into 4 subgroups. We suggest a subpial origin of group II IDEM ependymomas. We also advocate proliferation index estimation in grade II ependymomas to enable formulation of an optimal management plan.
Collapse
|
3
|
Wostrack M, Ringel F, Eicker SO, Jägersberg M, Schaller K, Kerschbaumer J, Thomé C, Shiban E, Stoffel M, Friedrich B, Kehl V, Vajkoczy P, Meyer B, Onken J. Spinal ependymoma in adults: a multicenter investigation of surgical outcome and progression-free survival. J Neurosurg Spine 2018; 28:654-662. [PMID: 29521579 DOI: 10.3171/2017.9.spine17494] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Spinal ependymomas are rare glial neoplasms. Because their incidence is low, only a few larger studies have investigated this condition. There are no clear data concerning prognosis and therapy. The aim of the study was to describe the natural history, perioperative clinical course, and local tumor control of adult patients with spinal ependymomas who were surgically treated under modern treatment standards. METHODS The authors performed a multicenter retrospective study. They identified 158 adult patients with spinal ependymomas who had received surgical treatment between January 2006 and June 2013. The authors analyzed the clinical and histological aspects of these cases to identify the predictive factors for postoperative morbidity, tumor resectability, and recurrence. RESULTS Gross-total resection (GTR) was achieved in 80% of cases. At discharge, 37% of the patients showed a neurological decline. During follow-up the majority recovered, whereas 76% showed at least preoperative status. Permanent functional deterioration remained in 2% of the patients. Transient deficits were more frequent in patients with cervically located ependymomas (p = 0.004) and in older patients (p = 0.002). Permanent deficits were independently predicted only by older age (p = 0.026). Tumor progression was observed in 15 cases. The 5-year progression-free survival (PFS) rate was 80%, and GTR (p = 0.037), WHO grade II (p = 0.009), and low Ki-67 index (p = 0.005) were independent prognostic factors for PFS. Adjuvant radiation therapy was performed in 15 cases. No statistically relevant effects of radiation therapy were observed among patients with incompletely resected ependymomas (p = 0.079). CONCLUSIONS Due to its beneficial value for PFS, GTR is important in the treatment of spinal ependymoma. Gross-total resection is feasible in the majority of cases, with acceptable rates of permanent deficits. Also, Ki-67 appears to be an important prognostic factor and should be included in a grading scheme for spinal ependymomas.
Collapse
Affiliation(s)
- Maria Wostrack
- 1Department of Neurosurgery, Klinikum rechts der Isar, Technical University of Munich
| | - Florian Ringel
- 1Department of Neurosurgery, Klinikum rechts der Isar, Technical University of Munich
- 8Department of Neurosurgery, University Clinic Johannes Gutenberg-University Mainz
| | - Sven O Eicker
- 4Department of Neurosurgery, University Medical Center Hamburg-Eppendorf
| | - Max Jägersberg
- 3Department of Neurosurgery, University of Geneva Medical Center, Geneva, Switzerland; and
| | - Karl Schaller
- 3Department of Neurosurgery, University of Geneva Medical Center, Geneva, Switzerland; and
| | | | - Claudius Thomé
- 5Department of Neurosurgery, Medical University Innsbruck, Austria
| | - Ehab Shiban
- 1Department of Neurosurgery, Klinikum rechts der Isar, Technical University of Munich
| | - Michael Stoffel
- 1Department of Neurosurgery, Klinikum rechts der Isar, Technical University of Munich
- 9Department of Neurosurgery, Helios Clinic, Krefeld, Germany
| | - Benjamin Friedrich
- 7Department of Neuroradiology, Klinikum rechts der Isar, Technical University of Munich
| | - Victoria Kehl
- 6Institute for Medical Statistics and Epidemiology, Technical University of Munich
| | | | - Bernhard Meyer
- 1Department of Neurosurgery, Klinikum rechts der Isar, Technical University of Munich
| | - Julia Onken
- 2Department of Neurosurgery, Charité University, Berlin
| |
Collapse
|
4
|
Tao X, Hou Z, Hao S, Zhang Q, Wu Z, Zhang J, Liu B. The Clinical Features and Surgical Outcomes of Spinal Cord Tanycytic Ependymomas: A Report of 40 Cases. World Neurosurg 2017. [PMID: 28647654 DOI: 10.1016/j.wneu.2017.06.111] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVE Spinal cord tanycytic ependymomas (TEs) rarely are reported because of extremely low incidence. Understanding of this disease is therefore poor. The aim of this study was to analyze the incidence and clinical, radiologic, pathologic, and prognostic features of spinal cord TEs. METHODS Approximately 4000 spinal cord tumors were resected surgically in Beijing Tiantan Hospital between April 2009 and May 2016. We identified all cases of pathologically proved TEs among these patients. RESULTS TEs accounted for approximately 1% of spinal cord tumors (40 of an estimated 4000). Patients with TE were a mean age of 40.0 years and had no significant sex preference (21 male and 19 female). The median diameter of the maximal tumor was 54.2 mm (range, 16-153 mm). The mean preoperative Japanese Orthopedic Association (JOA) score was 13.0. Radiologically, 47.5% (19/40) cases showed poorly defined tumor border, and 40% (16/40) of them showed preoperative syringomyelia. Gross total resection was achieved in 30 cases, subtotal resection in 8, and partial resection in 2. At the time of discharge, JOA score and neurologic function showed improvement in 26 cases (65%), no change in 12 cases (30%), and worsening in 2 cases (5%). At a median follow-up of 43 months (range, 7-101 months), 1- and 5-year progression-free survival rates were 100.0% and 97.5%, respectively. Only one patient had tumor recurrence which was found 30 months after surgery. No patient died of tumor recurrence. At the latest follow-up, JOA score showed improvement in 30 cases (75%), no change in 8 cases (20%), and worsening in 2 cases (5%). Univariate analysis revealed that tumor size and preoperative JOA score were significantly associated with the short-term outcomes. Meanwhile, age ≥40 years, tumor size ≥50 mm, non-gross total resection, and preoperative JOA score <14 were significantly associated with an increased risk of worsened long-term outcomes. Poorly defined tumor border and preoperative JOA score <14 significantly limited the extent of tumor resection. CONCLUSIONS Spinal cord TE is a rare subtype of ependymomas with low recurrence. Long-term survival can be expected, although poorly defined tumor border is an independent predictor of long-term outcomes. Microsurgical treatment of spinal cord TEs remains a formidable challenge due to the poorly defined border and critical neurovascular structures encasement. It is unnecessary for radical tumor resection at the cost of severe neurologic deficits.
Collapse
Affiliation(s)
- Xiaogang Tao
- Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
| | - Zonggang Hou
- Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
| | - Shuyu Hao
- Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
| | - Qi Zhang
- Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Zhen Wu
- Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
| | - Junting Zhang
- Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
| | - Baiyun Liu
- Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China; Department of Neurotrauma, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China; Nerve Injury and Repair Center of Beijing Institute for Brain Disorders, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Beijing Key Laboratory of Central Nervous System Injury, Beijing, China.
| |
Collapse
|
5
|
Zhang XP, Liu Y, Zhang D, Zheng Q, Wang C, Wang L, Li QC, Qiu XS, Wang EH. Cerebellar ependymoma with overlapping features of clear-cell and tanycytic variants mimicking hemangioblastoma: a case report and literature review. Diagn Pathol 2017; 12:28. [PMID: 28320419 PMCID: PMC5359883 DOI: 10.1186/s13000-017-0619-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Accepted: 03/14/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Imaging and histology of clear-cell ependymoma and cerebellum-based hemangioblastoma are similar; distinguishing between them is a diagnostic challenge. CASE PRESENTATION A 62-year-old Chinese woman presented with an intermittent headache of 8 years' duration. Computed tomography and magnetic resonance imaging revealed a mass in the cerebellum. Neurological imaging suggested hemangioblastoma (HB). Histologically, the tumor included cellular and paucicellular areas, in which cells were arranged in nests or diffusely distributed; and a highly vascular area, in which tumor cells were arranged in clusters and separated by capillaries. At low magnification, the tumor mimicked cellular HB, but at high magnification, tumor cells showed clear cytoplasm instead of the vacuolated cytoplasm typically observed in HB. Moreover, spindly, bipolar elements resembling tanycytes were observed within the nest structures. Although these features indicated the possibility of ependymoma, neither true ependymal rosettes nor an ependymal-lined profile was observed. The tumor was characterized by prominent vascularity, but glomeruloid formation was absent. We saw pleomorphism in foci of some tumor giant cells, but pathologic mitosis and palisaded necrosis were absent. Most tumor cells were positive for glial fibrillary acidic protein and S100. Epithelial membrane antigen was expressed with a paranuclear dot-like or a ring-like pattern. The Ki-67 index was approximately 2%. Considering the patient's symptom, neurological imaging, and pathological findings, she was diagnosed as cerebellar ependymoma (WHO grade II). CONCLUSIONS Here, we report a case of ependymoma with overlapping clear-cell and tanycytic features, and review the literature to evaluate its real incidence. Pathologists should consider this rare diagnosis when confronted with a similar presentation.
Collapse
Affiliation(s)
- Xiu-Peng Zhang
- Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, 110001, China.,Institute of Pathology and Pathophysiology, China Medical University, Shenyang, 110001, China
| | - Yang Liu
- Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, 110001, China. .,Institute of Pathology and Pathophysiology, China Medical University, Shenyang, 110001, China.
| | - Di Zhang
- Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, 110001, China.,Institute of Pathology and Pathophysiology, China Medical University, Shenyang, 110001, China
| | - Qin Zheng
- Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, 110001, China.,Institute of Pathology and Pathophysiology, China Medical University, Shenyang, 110001, China
| | - Chen Wang
- Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, 110001, China.,Institute of Pathology and Pathophysiology, China Medical University, Shenyang, 110001, China
| | - Liang Wang
- Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, 110001, China.,Institute of Pathology and Pathophysiology, China Medical University, Shenyang, 110001, China
| | - Qing-Chang Li
- Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, 110001, China.,Institute of Pathology and Pathophysiology, China Medical University, Shenyang, 110001, China
| | - Xue-Shan Qiu
- Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, 110001, China.,Institute of Pathology and Pathophysiology, China Medical University, Shenyang, 110001, China
| | - En-Hua Wang
- Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, 110001, China.,Institute of Pathology and Pathophysiology, China Medical University, Shenyang, 110001, China
| |
Collapse
|
6
|
Current therapy and the evolving molecular landscape of paediatric ependymoma. Eur J Cancer 2017; 70:34-41. [DOI: 10.1016/j.ejca.2016.10.013] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Revised: 09/25/2016] [Accepted: 10/12/2016] [Indexed: 01/13/2023]
|
7
|
Abstract
Over the past 150 years since Virchow's initial characterization of ependymoma, incredible efforts have been made in the classification of these tumors and in the care of pediatric patients with this disease. While the advent of modern neurosurgery and the optimization of radiation have provided significant gains, a more complex but incomplete picture of pediatric ependymomas has begun to form through a combination of international collaborations and detailed genetic and histologic characterizations. This review includes and synthesizes the clinical understanding of pediatric ependymoma and their developing molecular insight into what is truly a family of malignancies in which distinct members require different surgical approaches, radiation plans, and targeted therapies.
Collapse
Affiliation(s)
- Nicholas A Vitanza
- Division of Child Neurology, Department of Neurology, Lucile Packard Children's Hospital at Stanford, Stanford University, Palo Alto, CA, USA
| | - Sonia Partap
- Division of Child Neurology, Department of Neurology, Lucile Packard Children's Hospital at Stanford, Stanford University, Palo Alto, CA, USA
| |
Collapse
|
8
|
Kutlay M, Cetinkal A, Kaya S, Demircan MN, Velioglu M, Berber U. Pediatric anaplastic parenchymal ependymoma: case report. Childs Nerv Syst 2011; 27:501-5. [PMID: 21110032 DOI: 10.1007/s00381-010-1346-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2009] [Accepted: 11/24/2009] [Indexed: 11/27/2022]
Affiliation(s)
- Murat Kutlay
- Department of Neurosurgery, GATA Haydarpasa Training Hospital, Istanbul, Turkey
| | | | | | | | | | | |
Collapse
|
9
|
Senetta R, Miracco C, Lanzafame S, Chiusa L, Caltabiano R, Galia A, Stella G, Cassoni P. Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes. Neuro Oncol 2010; 13:176-83. [PMID: 21059755 DOI: 10.1093/neuonc/noq160] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Supratentorial ependymomas account for a minority of intracranial ependymomas, which still have uncertain prognostic markers. Among them, epidermal growth factor receptor (EGFR) overexpression correlates with a poor prognosis. In glioblastoma cells, EGFR function has been reported to be regulated by its migration from cell membrane infoldings called caveolae and by its colocalization with the caveolae-associated protein caveolin-1 (cav-1). Therefore, we decided to investigate cav-1 expression and coexpression with EGFR in a series of adult intracranial ependymomas. We analyzed 22 adult supratentorial ependymomas and compared tumor grades as determined by the WHO classification and patient survival rates with the expression of EGFR, cav-1, and p53 and the values of the proliferation marker Ki-67, all tested by immunohistochemistry; in addition, we investigated the mutational profile of cav-1. The results demonstrate that the tumor grade is directly correlated with EGFR, Ki-67, and cav-1 expression only, whereas (by univariate analysis) the expression of all the studied markers, as well as the tumor histological grade, significantly correlated with the patient's overall survival (OS). By multivariate analysis using the Cox proportional hazards model, among all variables considered, cav-1 was the only independent prognostic marker related to OS (relative risk = 13.92; P = .013). Among grade II ependymomas, only cav-1 correlated with poor OS (P = .011), distinguishing 2 distinct subgroups of tumors with different outcomes despite sharing identical grading. All the patients studied carried wild-type cav-1 sequences, demonstrating that cav-1 overexpression is not driven by activating mutations, as previously reported in other tumor types. Interestingly, after stratifying all cases into 4 distinct groups according to cav-1 and EGFR expression (cav-1+/EGFR+, cav-1-/EGFR-, cav-1+/EGFR-, and cav-1-/EGFR+), the coexpression of cav-1 and EGFR identified a subset of patients with definitively poor prognoses. Further studies are needed to support this evidence on a larger scale and to clarify how cav-1 and EGFR interaction can influence tumor aggressiveness.
Collapse
Affiliation(s)
- Rebecca Senetta
- Department of Biomedical Sciences and Human Oncology, University of Turin, Via Santena 7, 10100 Turin, Italy
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Nagamatsu KI, Kumabe T, Watanabe M, Nakazato Y, Tominaga T. Differentiation of clear cell ependymoma of the cerebellum from hemangioblastoma by thallium-201 single photon emission computed tomography-case report-. Neurol Med Chir (Tokyo) 2009; 49:608-11. [PMID: 20035139 DOI: 10.2176/nmc.49.608] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A 57-year-old man suffered from dizziness for about one year and truncal ataxia for about one month. Magnetic resonance imaging demonstrated a cystic tumor with a homogeneously enhanced mural nodule located in the cerebellar vermis. Computed tomography angiography revealed a hypervascular nodule. These findings were compatible with hemangioblastoma. Thallium-201 single photon emission computed tomography ((201)Tl-SPECT) showed moderately high uptake in the early phase and moderately high retention in the delayed phase, whereas hemangioblastoma shows almost no retention in the delayed phase. The patient underwent total removal of the tumor. The histological diagnosis was clear cell ependymoma (CCE). CCE is a rare subtype of ependymoma, which resembles hemangioblastoma in histological and neuroimaging findings, but is considerably more aggressive. (201)Tl-SPECT can provide useful information for the preoperative differential diagnosis of infratentorial CCE and hemangioblastoma.
Collapse
Affiliation(s)
- Ken-ichi Nagamatsu
- Department of Neurosurgery, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi, Japan
| | | | | | | | | |
Collapse
|
11
|
Shintaku M, Sakamoto T. Tanycytic ependymoma of the filum terminale with pleomorphic giant cells. Brain Tumor Pathol 2009; 26:79-82. [DOI: 10.1007/s10014-009-0252-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2009] [Accepted: 04/13/2009] [Indexed: 10/20/2022]
|
12
|
Tamburrini G, D'Ercole M, Pettorini BL, Caldarelli M, Massimi L, Di Rocco C. Survival following treatment for intracranial ependymoma: a review. Childs Nerv Syst 2009; 25:1303-12. [PMID: 19387655 DOI: 10.1007/s00381-009-0874-y] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2009] [Indexed: 11/25/2022]
Abstract
The actual definition of survival rates following treatment for intracranial ependymomas is substantially influenced by the strict interaction among different factors. Age, location, and grading, for example, act together, negatively influencing the prognosis of younger children also invariably influenced by the more demanding role of surgery and the still limited use, up to recently, of radiotherapy under 3 years of age. In the same direction, the worse prognosis in most series of infratentorial ependymomas if compared with their supratentorial counterpart should be cautiously considered, midline posterior fossa tumors having completely different implications from those originating or predominantly extending to the cerebellopontine angle, where the extent of surgery has more invariably to compare with patients' quality of life. New radiotherapic regimens and their applications in infancy are promisingly demonstrating an improvement of present prognostic criteria, with the limit of still insufficient information on their long-term secondary effects. Similarly, molecular biology research studies, though still in their preclinical stage, are prompting to change the concept of a substantially chemoresistant tumor helping to stratify these lesions with the final aim of targeted pharmacological therapies. In the present review paper, we investigated singularly the role that the more commonly considered prognostic factors have had in the literature on survival of children affected by intracranial ependymomas, trying to elucidate their cumulative effect on the actual knowledge of this issue.
Collapse
Affiliation(s)
- G Tamburrini
- Pediatric Neurosurgery, Institute of Neurosurgery, Catholic University Medical School, Largo A. Gemelli, 8, 00168, Rome, Italy.
| | | | | | | | | | | |
Collapse
|
13
|
A case of cervicomedullary junction tanycytic ependymoma associated with marked cyst formation. Brain Tumor Pathol 2009; 22:29-33. [PMID: 18095101 DOI: 10.1007/s10014-005-0174-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2005] [Accepted: 02/16/2005] [Indexed: 10/25/2022]
Abstract
Tanycytic ependymomas are a subtype of ependymomas that were formally recognized as a new pathological entity in the latest World Health Organization (WHO) classification of 2000. They occur mostly in the spinal cord. Only a few reports have analyzed the proliferative potentials of these tumors; however, it has been reported that the MIB-1 labeling index of tanycytic ependymoma is lower than that of other subtypes of WHO grade II ependymomas. We report a rare case of cervicomedullary junction tanycytic ependymoma associated with marked cyst formation. A 62-year-old man had a history of progressive gait disturbance, diplopia, and swallowing disturbance over a one-month period prior to admission. Magnetic resonance imaging (MRI) showed a cystic mass with a mural nodule at the cervicomedullary junction with Gd-DTPA enhancement. Cyst-subarachnoid shunt was performed using a far lateral approach. After 6 years, however, the man was readmitted to the hospital because of reaccumulation of the cyst. Partial removal of a mural nodule and a cyst-subarachnoid shunt were performed simultaneously by a midline suboccipital approach. The pathological diagnosis was tanycytic ependymoma. Postoperatively, the patient recovered well and was discharged from the hospital without further treatment. Most of the tumor cells had small, round nuclei; pleomorphism was minimal. The cytoplasm was dilated. The tumor cells were positive for EMA and s-100, and negative for CD-34. GFAP was not determined due to difficulty caused by background glial processes. The MIB-1 labeling index was less than 1%. Ultrastructurally, the tumor cells had ependymal cell features, such as desmosomes and microvilli. Based on these findings, the pathological diagnosis was tanycytic ependymoma.
Collapse
|
14
|
Infratentorial ependymomas: prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients. Acta Neurochir (Wien) 2009; 151:947-60. [PMID: 19499166 DOI: 10.1007/s00701-009-0417-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2009] [Accepted: 05/12/2009] [Indexed: 10/20/2022]
Abstract
OBJECT This study was undertaken to analyze outcomes and to assess the prognostic impact of age, location, surgery, radiotherapy (RT), and histopathology in a series of adult infratentorial ependymomas. METHODS This was a retrospective study of a population of 106 adult patients with infratentorial ependymomas diagnosed between 1990 and 2004. A central pathological review of all cases was performed. Grading was according to the WHO and Marseille's neograding classifications. RESULTS The series consisted of 58 males (54.7%) and 48 females (45.3%) in the age range of 18-82 years. Using the WHO classification, 88 patients (83.0%) had grade II and 18 patients (17.0%) grade III ependymomas. Using the Marseille's neograding system, 91 patients were low-grade and 15 high-grade. Gross total resection was achieved in 66 patients (62.3%). Thirty-seven patients (35.0%) received adjuvant RT. The 5- and 10-year overall survival rates for the entire cohort were 86.1% and 80.5%, respectively. On multivariate analysis, a preoperative Karnofski performance status score > 80, no recessus lateral extension and a low histological grade (Marseille's grading) were associated with a longer overall survival. The 5- and 10-year progression-free survival rates for the entire cohort were 70.8% and 57.7%, respectively. On multivariate analysis, no recessus lateral extension, gross total resection and a low histological grade (Marseille's grading) were associated with a longer progression-free survival. Adjuvant RT was significantly associated with a better overall and progression-free survival in incompletely resected WHO grade II ependymomas. CONCLUSIONS This study highlights the key role of histology in the clinical outcome and the fact that gross total resection is a main prognostic factor and the treatment of choice for posterior fossa ependymomas. The use of adjuvant RT in patients with incompletely resected WHO grade II ependymomas appears beneficial, but its effect on high-grade tumors remains to be determined.
Collapse
|
15
|
Kilday JP, Rahman R, Dyer S, Ridley L, Lowe J, Coyle B, Grundy R. Pediatric ependymoma: biological perspectives. Mol Cancer Res 2009; 7:765-86. [PMID: 19531565 DOI: 10.1158/1541-7786.mcr-08-0584] [Citation(s) in RCA: 129] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Pediatric ependymomas are enigmatic tumors that continue to present a clinical management challenge despite advances in neurosurgery, neuroimaging techniques, and radiation therapy. Difficulty in predicting tumor behavior from clinical and histological factors has shifted the focus to the molecular and cellular biology of ependymoma in order to identify new correlates of disease outcome and novel therapeutic targets. This article reviews our current understanding of pediatric ependymoma biology and includes a meta-analysis of all comparative genomic hybridization (CGH) studies done on primary ependymomas to date, examining more than 300 tumors. From this meta-analysis and a review of the literature, we show that ependymomas in children exhibit a different genomic profile to those in adults and reinforce the evidence that ependymomas from different locations within the central nervous system (CNS) are distinguishable at a genomic level. Potential biological markers of prognosis in pediatric ependymoma are assessed and the ependymoma cancer stem cell hypothesis is highlighted with respect to tumor resistance and recurrence. We also discuss the shifting paradigm for treatment modalities in ependymoma that target molecular alterations in tumor-initiating cell populations.
Collapse
Affiliation(s)
- John-Paul Kilday
- The Children's Brain Tumour Research Centre, University of Nottingham, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
16
|
Milde T, Pfister S, Korshunov A, Deubzer HE, Oehme I, Ernst A, Starzinski-Powitz A, Seitz A, Lichter P, von Deimling A, Witt O. Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. Genes Chromosomes Cancer 2009; 48:229-38. [PMID: 19025795 DOI: 10.1002/gcc.20635] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Nonresectable ependymomas are associated with poor prognosis despite intensive radiochemotherapy and radiation. The molecular pathogenesis of ependymoma initiation and progression is largely unknown. We here present a case of therapy-refractory, progressive ependymoma with cerebrospinal as well as extraneural metastases, which allowed us for the first time to follow the stepwise accumulation of chromosome aberrations during disease progression. Genome-wide DNA copy-number analysis showed sequential deletions on chromosomes 1, 9, and 14 as well as a homozygous deletion of the CDKN2A locus, underscoring its role in tumor progression. Gradual loss at 1p36 was associated with loss of protein expression of the putative tumor suppressor gene AJAP1/SHREW1. In summary, this is the first report on acquired genomic aberrations in ependymoma over time pointing to novel candidate tumor suppressor genes. This analysis provides molecular insights into the chronology of genetic events in this case from initial localized tumor to widespread metastasized disease.
Collapse
Affiliation(s)
- Till Milde
- Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center, Heidelberg, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Sharma MC, Ghara N, Jain D, Sarkar C, Singh M, Mehta VS. A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas. Neuropathology 2009; 29:148-55. [DOI: 10.1111/j.1440-1789.2008.00962.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
18
|
Ridley L, Rahman R, Brundler MA, Ellison D, Lowe J, Robson K, Prebble E, Luckett I, Gilbertson RJ, Parkes S, Rand V, Coyle B, Grundy RG. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol 2008; 10:675-89. [PMID: 18701711 PMCID: PMC2666244 DOI: 10.1215/15228517-2008-036] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2007] [Accepted: 02/25/2008] [Indexed: 01/26/2023] Open
Abstract
Pediatric ependymomas are enigmatic tumors, and their clinical management remains one of the more difficult in pediatric oncology. The identification of biological correlates of outcome and therapeutic targets remains a significant challenge in this disease. We therefore analyzed a panel of potential biological markers to determine optimal prognostic markers. We constructed a tissue microarray from 97 intracranial tumors from 74 patients (WHO grade II-III) and analyzed the candidate markers nucleolin, telomerase catalytic subunit (hTERT; antibody clone 44F12), survivin, Ki-67, and members of the receptor tyrosine kinase I (RTK-I) family by immunohistochemistry. Telomerase activity was determined using the in vitro-based telomere repeat amplification protocol assay, and telomere length was measured using the telomere restriction fragment assay. Primary tumors with low versus high nucleolin protein expression had a 5-year event-free survival of 74%+/-13% and 31%+/-7%, respectively. Multivariate analysis identified low nucleolin expression to be independently associated with a more favorable prognosis (hazard ratio=6.25; 95% confidence interval, 1.6-24.2; p=0.008). Ki-67 and survivin correlated with histological grade but not with outcome. Immunohistochemical detection of the RTK-I family did not correlate with grade or outcome. Telomerase activity was evident in 19 of 22 primary tumors, with telomere lengthening and/or maintenance occurring in five of seven recurrent cases. Low nucleolin expression was the single most important biological predictor of outcome in pediatric intracranial ependymoma. Furthermore, telomerase reactivation and maintenance of telomeric repeats appear necessary for childhood ependymoma progression. These findings require corroboration in a clinical trial setting.
Collapse
Affiliation(s)
- Lee Ridley
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| | - Ruman Rahman
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| | - Marie-Anne Brundler
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| | - David Ellison
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| | - James Lowe
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| | - Keith Robson
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| | - Emma Prebble
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| | - Inga Luckett
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| | - Richard J. Gilbertson
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| | - Sheila Parkes
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| | - Vikki Rand
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| | - Beth Coyle
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| | - Richard G. Grundy
- Children’s Brain Tumor Research Centre, University of Nottingham, Nottingham, UK (L.R., R.R., J.L., K.R., V.R., B.C., R.G.G.); Department of Pathology (M.-A.B.) and West Midlands Regional Children’s Tumor Registry (S.P.), Birmingham Children’s Hospital, Birmingham, UK; St. Jude Children’s Research Hospital, Memphis, TN, USA (D.E., I.L., R.J.G.); Regional Genetics Laboratory, Birmingham Women’s Hospital, Birmingham, UK (E.P.); Department of Neuropathology, Nottingham University Hospital, Queens Medical Centre, Nottingham, UK (J.L., K.R.)
| |
Collapse
|
19
|
Abstract
The World Health Organization recently updated its classification of central nervous system tumors, adding 8 entities, as well as defining new variants and morphologic patterns of existing entities. Despite the continued refinement of brain tumor histologic classification and grading, there remain some diagnostic "gray zones" that challenge general surgical pathologists and neuropathologists alike. These include the presence of oligodendroglial features in (mixed) oligoastrocytomas and glioblastomas (GBMs), GBM variants (such as small cell GBM), meningioma classification and grading, medulloblastoma variants, ependymoma grading, the presence of "neuronal features" in otherwise morphologically classic gliomas, and low-grade gliomas with high Ki-67 labeling indices. In the current review, we discuss these issues and offer some practical guidelines for dealing with problematic cases.
Collapse
|
20
|
Jain D, Sharma MC, Arora R, Sarkar C, Suri V. Clear cell ependymoma: a mimicker of oligodendroglioma – report of three cases. Neuropathology 2008; 28:366-71. [DOI: 10.1111/j.1440-1789.2008.00895.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
21
|
Metellus P, Figarella‐Branger D, Guyotat J, Barrie M, Giorgi R, Jouvet A, Chinot O. Supratentorial ependymomas: Prognostic factors and outcome analysis in a retrospective series of 46 adult patients. Cancer 2008; 113:175-85. [DOI: 10.1002/cncr.23530] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
22
|
Zhang S, Wang X, Zhang Z, Chen Y. Tanycytic ependymoma arising from the right lateral ventricle: a case report and review of the literature. Neuropathology 2008; 28:427-32. [PMID: 18312548 DOI: 10.1111/j.1440-1789.2007.00857.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A 38-year-old man presented with a year-long history of worsening headache. Neuroradiological findings showed that a solid cystic mass occupied the right lateral ventricle. Histologically, the tumor composed of nuclear dense zones consisting of a cluster of spindle cells and fibrillary zones consisting of streaming of cell processes. The tumor cells showed the characteristics of monopolar or bipolar processes. Some tumor cell processes extended to the vessel wall and formed ill-defined perivascular rosettes. No mitoses or necrosis were found. The cells presented positive for GFAP, S-100 protein, vimentin, Nestin and neurofilament, and dotlike positive for epithelial membrane antigen, but negative for Syn and NeuN. Four cases of tanycytic ependymoma arising from the lateral ventricle have been reported in literature. Histological differential diagnosis includes spindle-shaped neuroepithelial tumors, such as pilocytic astrocytoma, fibrillary astrocytoma and schwannoma. Tanycytic ependymoma has slightly better prognosis than other ependymoma subtypes.
Collapse
Affiliation(s)
- Sheng Zhang
- Department of Pathology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
| | | | | | | |
Collapse
|
23
|
Figarella-Branger D, Metellus P, Barrié M, Maues de Paula A, Fernandez C, Polivka M, Vital A, Labrousse F, Vignaud JM, Laquerrière A, Rousselet MC, Lacroix C, Saikali S, Chapon F, Gontier MF, Chrétien F, Babin P, Rigau V, Vandenbos F, Peoc'h M, Kujas M, Chinot O, Gouvernet J, Giorgi R, Guyotat J, Jouvet A. Épendymomes intracrâniens de l'adulte. Diagnostic histologique et facteurs histopronostiques. Neurochirurgie 2007; 53:76-84. [PMID: 17445840 DOI: 10.1016/j.neuchi.2006.11.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2006] [Accepted: 11/29/2006] [Indexed: 11/22/2022]
Abstract
BACKGROUND Intracranial ependymomas are rare in adults and histopathological prognostic factors are poorly determined. PURPOSE A retrospective multicentric study was conducted in France in order to assess the prognostic value of histology. MATERIAL Between 1990 and 2004, 216 adult patients with newly diagnosed ependymomas were treated in 19 French centers. Eligibility required institutional histopathological confirmation of an ependymoma and available clinical history and MRI features (see comparison paper). METHODS Histological preparations and one paraffin embedded block from each patient were sent to Pr D. Figarella-Branger in Marseille. Central review by four neuropathologists (D. Figarella-Branger, A. Maues de Paula, C. Fernandez and A. Jouvet) was performed. Specimens for which all pathologists agreed with the histological diagnosis of ependymomas were included, whereas cases for which all disagree were excluded and reclassified. In the event of doubt and/or discrepancies between pathologists immunostaining was performed in order to reach a consensus diagnosis. Diagnostic of ependymomas was confirmed in 121 cases (56%). In theses cases, ependymomas were classified according to the WHO system (subtype and grade). The potential prognostic value (overall survival OS and disease free survival DFS) of the following histological parameters was examined: perivascular pseudorosettes, ependymal rosettes, hyalinized vessels, mitotic index, microvascular proliferation, necrosis, area of increased cellularity, nuclear atypia, brain invasion and Mib-1 labelling index. RESULTS Among the 121 ependymomas, 88 were grade II (47 classic, 17 cellular, 2 papillar, 6 clear cells and 16 tanicytic) and 33 grade III. WHO grading, occurrence of microvascular proliferation, necrosis, nuclear atypia and high proliferative index were correlated with both OS and DFS. Moreover, quantification of certain parameters enabled a reproducible grading system correlated with both OS and DFS.
Collapse
Affiliation(s)
- D Figarella-Branger
- Service d'anatomie pathologique et de neuropathologie, hôpital de la Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Ito T, Ozaki Y, Nakamura H, Tanaka S, Nagashima K. A case of tanycytic ependymoma arising from the cerebral hemisphere. Brain Tumor Pathol 2006; 23:91-5. [DOI: 10.1007/s10014-006-0208-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2006] [Accepted: 06/22/2006] [Indexed: 10/24/2022]
|
25
|
Tamiolakis D, Papadopoulos N, Venizelos I, Lambropoulou M, Nikolaidou S, Bolioti S, Kiziridou A, Manavis J, Alexiadis G, Simopoulos C. Loss of chromosome 1 in myxopapillary ependymoma suggests a region out of chromosome 22 as critical for tumour biology: a FISH analysis of four cases on touch imprint smears. Cytopathology 2006; 17:199-204. [PMID: 16879268 DOI: 10.1111/j.1365-2303.2006.00287.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
OBJECTIVE Ependymomas are glial tumours. They constitute approximately 5-10% of intracranial tumours and are tumours which can recur. Predictive factors of outcome in ependymomas are not well established. Karyotypic studies are relatively scarce and loss of chromosome 22 has been described to correlate with recurrence. We are unaware of any reports involving chromosome 1 aberrations in the malignant progression of ependymomas. METHODS Cytogenetic analysis of four myxopapillary ependymomas was performed using double target fluorescent in situ hybridization (FISH), focusing on chromosomes 1 and 22. RESULTS One patient's tumour had recurred. FISH was performed on 500 nuclei/tumours. All four cases showed a loss of chromosome 22q while only one showed an additional loss of chromosome 1p, and this was the one that recurred. CONCLUSIONS We support the presence of a tumour suppressor gene on 1p associated with relapse in myxopapillary ependymomas and suggest that status of chromosome 1p by FISH may indicate a high-risk group of patients harbouring this tumour. More studies of this type are needed towards this direction as our results refer to a minimal number of individuals analysed.
Collapse
Affiliation(s)
- D Tamiolakis
- Department of Cytology, Regional Hospital of Chania, Thrace, Greece
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Ragel BT, Townsend JJ, Arthur AS, Couldwell WT. Intraventricular tanycytic ependymoma: case report and review of the literature. J Neurooncol 2005; 71:189-93. [PMID: 15690137 DOI: 10.1007/s11060-004-1371-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE AND IMPORTANCE Tanycytic ependymomas are a rare ependymoma subtype showing a marked predilection for the spine, with only a few reports of supratentorial tumors. We present a case of a tanycytic ependymoma arising from the lateral and third ventricle. CLINICAL PRESENTATION The patient was a 55-year-old woman who complained of intermittent, progressively worsening dysequilibrium for several months. The neurologic exam in the neurosurgery clinic was without deficit. INTERVENTION MRI of the brain revealed a 3-cm, minimally enhancing lesion centered in the superior aspect of the third ventricle. The tumor involved the left wall of the third ventricle, the septum pellucidum, and the anterior horn of the left lateral ventricle. Surgery was recommended for diagnosis and to prevent obstructive hydrocephalus. A gross total resection was achievedvia a transcallosal approach. Postoperatively, the patient remained neurologically intact. CONCLUSION The long-term prognosis for tanycytic ependymomas is the same or slightly better than for other ependymoma subtypes. The current treatment plan includes gross total resection followed by radiologic surveillance. Repeat resection or radiation treatment will be recommended in the event of recurrence.
Collapse
Affiliation(s)
- Brian T Ragel
- Department of Neurosurgery, University of Utah Health Sciences Center, Salt Lake City, UT 84132-2303, USA
| | | | | | | |
Collapse
|
27
|
Richards AL, Rosenfeld JV, Gonzales MF, Ashley D, Mc Lean C. Supratentorial tanycytic ependymoma. J Clin Neurosci 2004; 11:928-30. [PMID: 15519882 DOI: 10.1016/j.jocn.2004.03.022] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2004] [Accepted: 03/22/2004] [Indexed: 10/26/2022]
Abstract
Tanycytic ependymoma is a rare fibrillary variant of ependymoma with a predilection for the spinal cord. We present an unusual supratentorial subcortical tanycytic ependymoma in a 17-year old male presenting with seizures. Only two other cases of subcortical tanycytic ependymoma have been reported.
Collapse
Affiliation(s)
- Amanda L Richards
- Department of Neurosurgery and Surgery, The Alfred Hospital, Commercial Road, Prahran, Vic. 3181, Australia
| | | | | | | | | |
Collapse
|
28
|
Wolfsberger S, Fischer I, Höftberger R, Birner P, Slavc I, Dieckmann K, Czech T, Budka H, Hainfellner J. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol 2004; 28:914-20. [PMID: 15223962 DOI: 10.1097/00000478-200407000-00011] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Histopathologic grading of ependymomas is considered unreliable in terms of outcome prediction. Quantification of tumor cell proliferation may be useful for outcome prediction. We analyzed prognostic and predictive values of tumor cell proliferation rates using anti-Ki-67 antigen (MIB-1 antibody) and anti-topoisomerase-IIalpha (Topo-IIalpha) immunolabeling on tumor samples of 103 consecutive ependymoma patients 0.1 to 74.4 years of age. In this patient cohort, the following clinical and histopathologic parameters showed significant correlation with overall survival on univariate analysis: extent of resection, use of an operating microscope, radiologic imaging with computed tomography and/or magnetic resonance imaging, radiotherapy, tumor size (cutoff 3 cm), WHO grade, presence of tumor necrosis, increased cellularity, microvascular proliferation, and low/high Ki-67 and Topo-IIalpha indices (cutoff 20.5% and 9.4%, respectively). On multivariate analysis, incomplete resection and high Ki-67 index remained independent factors of adverse patient outcome. In Kaplan-Meier survival analysis, low (<20.5%) or high (> or = 20.5%) Ki-67 indices predicted favorable (> or = 5 years) or unfavorable (<5 years) patient outcome at 79% and 70%, respectively. We conclude that Ki-67 immunolabeling index is an independent prognostic factor and accurate predictor of outcome in patients with intracranial ependymoma. Thus, assessment of Ki-67 index in intracranial ependymoma is useful for outcome prediction in the routine diagnostic setting.
Collapse
Affiliation(s)
- Stefan Wolfsberger
- Department of Neurosurgery, University of Vienna Medical School, Vienna General Hospital, Vienna, Austria
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Kojima A, Yamaguchi N, Okui S, Kamiya M, Hirato J, Nakazato Y. Parenchymal anaplastic ependymoma with intratumoral hemorrhage: a case report. Brain Tumor Pathol 2003; 20:85-8. [PMID: 14756446 DOI: 10.1007/bf02483452] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
We report an unusual case of a 56-year-old woman with a supratentorial anaplastic ependymoma localized in the parenchyma without continuity with the ventricular system and brain surface. The patient presented with vertigo, and a calcified mass was detected in the left temporal parenchyma. Five years later, she had seizure of the right extremities. Computed tomographic scanning and magnetic resonance imaging revealed an enhanced mass with an intratumoral hemorrhage adjacent to the calcified mass. Subtotal removal of the tumor was performed. The histological analysis revealed that the tumor was an anaplastic ependymoma. After focal radiation therapy (50 Gy), the outcome was favorable, although the residual lesion was still seen on the images. Ependymomas usually arise from the cells lining the ventricular system and the central canal of the spinal cord. We discuss the summary of published cases of supratentorial ectopic ependymoma since the first case in 1995.
Collapse
Affiliation(s)
- Atsuhiro Kojima
- Department of Neurosurgery, Saitama Municipal Hospital, Saitama, 2460 Mimuro, Midori-ku, Saitama-shi, Saitama 336-0911, Japan.
| | | | | | | | | | | |
Collapse
|